Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CANOPY-1: Canakinumab + Pembrolizumab + Chemotherapy in First-Line NSCLC
NCT03631199Phase 3Terminated
- Sponsor
- Novartis
- Start
- Dec 2018
- Primary completion
- Aug 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 41
01
Overview
A Phase 3 trial of canakinumab in non-small cell lung cancer (NSCLC), sponsored by Novartis. Started Dec 2018; status: terminated.
02
Drugs
canakinumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03631199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03631199.